T1	p 205 243	patients with atrial fibrillation ( AF
T2	p 689 711	( 44 countries ) trial
T3	p 715 770	patients with nonvalvular AF and at least 1 risk factor
T4	p 813 857	total of 18,113 patients . Patients who were
T5	p 955 964	including
T6	p 977 978	)
T7	p 1213 1220	minimum
T8	p 1378 1396	naive patients and
T9	i 30 35	RE-LY
T10	i 63 105	long-term anticoagulant therapy , warfarin
T11	i 122 165	dabigatran . Vitamin K antagonists ( VKAs )
T12	i 284 293	etexilate
T13	i 354 385	thrombin inhibitor dabigatran .
T14	i 429 439	laboratory
T15	i 478 488	warfarin (
T16	i 560 570	dabigatran
T17	i 616 621	RE-LY
T18	i 1430 1440	dabigatran
T19	o 503 523	normalized ratio 2-3
T20	o 965 978	hemorrhagic )
T21	o 982 1017	systemic embolism . Safety outcomes
T22	o 1022 1063	bleeding , liver function abnormalities ,
T23	o 1068 1103	other adverse events . Adjudication
T24	o 1195 1198	450
T25	o 1358 1373	VKA-experienced
T26	o 1567 1571	risk
T27	o 1593 1600	general